Last reviewed · How we verify
PoliorixTM
Poliorix is an inactivated poliomyelitis vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes (1, 2, and 3).
Poliorix is an inactivated poliomyelitis vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes (1, 2, and 3). Used for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3 in infants and children.
At a glance
| Generic name | PoliorixTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses without causing disease. Vaccination induces the production of neutralizing antibodies against poliovirus serotypes 1, 2, and 3, providing protection against poliomyelitis infection. This is a component of routine childhood immunization schedules in many countries.
Approved indications
- Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3 in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (PHASE4)
- Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers (PHASE3)
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers (PHASE3)
- A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |